This multicenter retrospective study revealed that high serum Alb level (≥3.5 g/dL) is a valuable predictive factor for the development of irAEs and that the development of multiple irAEs is a favorable prognostic factor for NSCLC patients undergoing chemoimmunotherapy. The gene discussed is ALB; the disease is non-small cell lung carcinoma.